檢體功效檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按產品/服務、類型、最終用戶、地區和競爭對手分類，2021-2031年

全球檢體功效測試市場預計將從 2025 年的 32.6 億美元成長到 2031 年的 49.5 億美元，複合年成長率為 7.21%。

這種專門的篩檢流程用於檢驗生物樣本的完整性，檢測是否存在檢體替換、稀釋或偽造用於藥物分析的樣本的行為。推動該市場發展的主要因素是嚴格的職場安全監管要求，以及在安全至關重要的行業中降低企業責任的必要性。藥物濫用的日益猖獗進一步加劇了這一需求，因此需要強力的檢驗通訊協定來確保檢測的準確性。例如，美國藥物濫用和精神健康服務管理局 (SAMHSA) 在 2024 年報告稱，過去一年中報告使用過非法藥物的人數比例上升至 25.5%，凸顯了採取有效篩檢措施的緊迫性。

儘管存在這些成長要素，但由於樣本處理技術的日益複雜化，例如使用高品質的合成尿液和先進的掩蔽劑，市場面臨著巨大的挑戰。這些變通方法迫使實驗室持續投資於複雜的分析技術，導致營運成本增加。此外，這也為努力維持全面有效性標準的小規模實驗室帶來了財務障礙。

市場促進因素

全球非法藥物濫用日益猖獗的是檢體有效性檢測市場的主要驅動力，也因此更需要嚴格的篩檢程序來驗證生物檢體的真實性。隨著國際毒品消費率的上升，檢測實驗室不得不處理更多樣本，這從統計學角度來看，增加了遇到被篡改或替換以掩蓋近期吸毒行為的樣本的可能性。這種消費量的激增迫使檢測機構將有效性檢體納入其分析流程的標準環節，以防止出現假陰性結果並維持檢測的準確性。根據聯合國毒品犯罪防制署發布的《2024年世界毒品報告》，2022年全球吸毒人數達到2.92億，比過去十年成長了20%，凸顯了採取強力的檢驗措施的必要性。

市場成長也受到職場藥物檢測和企業安全計畫擴展的推動，尤其是在交通運輸和製造業等安全至關重要的行業。雇主越來越強制要求進行包括療效參數在內的全面篩檢，以降低法律責任並維護職業安全標準，這促使商業檢測實驗室採用自動化療效檢測來應對激增的員工檢體。根據Quest Diagnostics發布的2024年5月年度藥物檢測指數，2023年美國員工的整體藥物陽性率維持在5.7%的水平，凸顯了雇主面臨的持續挑戰。此外，歐洲藥物和藥物依賴監測中心估計，2024年歐盟約有2,280萬成年人在過去一年中使用過大麻，這強調了製定統一的國際療效標準的必要性。

市場挑戰

檢體處理技術的日益複雜化是全球檢體有效性檢測市場面臨的主要阻礙因素。隨著越來越多的人使用先進的合成尿液和掩蔽劑來規避標準篩檢，實驗室被迫投入巨資研發高精度分析技術。這種需求顯著增加了營運成本和資金需求，對缺乏資源支持全面有效性標準的小規模實驗室而言，構成了巨大的財務障礙。

因此，高成本最終轉嫁給了終端用戶，隨著服務供應日益集中在大型營運商手中，市場的擴充性也下降。根據美國國家無毒工作場所聯盟（National Drug-Free 職場 Alliance）預測，到2024年，檢體替換的發生率預計將激增600%以上，凸顯了此類規避手段的快速蔓延。篡改行為的急劇增加迫使該行業不斷投入資源進行昂貴的檢驗系統升級，這直接阻礙了市場的財務永續性和成長。

市場趨勢

為了防止篡改，口腔液檢體檢驗檢測作為一種替代傳統尿液檢查的方法，正被日益廣泛地採用。與需要保護隱私的尿液採集不同，口腔液檢體的採集是在直接觀察下進行的，這顯著降低了檢體被替換或被合成藥物污染的風險。此方法無需二次化學分析即可自然提高檢體的可靠性，從而加速了其在法規結構中的應用。根據First Advantage發布的《2024年度趨勢報告》，在過去兩年中，基於口腔液的藥物篩檢使用量增加了74%，目前佔所有篩檢的30%。這表明檢測策略正在轉向一種能夠從根本上確保檢體完整性的檢測方式。

同時，市場正轉向照護現場(POC) 解決方案，以在安全至關重要的領域促進即時決策。各機構擴大採用攜帶式診斷工具，在現場檢驗檢體的有效性，從而有效避免中心檢查室處理帶來的延誤和儲存複雜性。這些設備通常整合了自動有效性檢查功能，可即時確保檢體的充足性和真實性。根據 OraSure Technologies 發布的 2024 年第三季財報，診斷業務營收年增 13%。這主要得益於快速檢測產品的強勁銷售，凸顯了業界對能夠提供即時檢驗結果的分散式篩檢方法的日益依賴。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：檢體功效測試的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品/服務分類（試劑、校正試劑/品管、檢測試劑盒、耗材、服務）
  • 按類型（檢查室檢測、快速/即時檢測）
  • 按最終使用者（職場、藥物篩檢檢查室、疼痛管理中心、戒毒康復中心等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美檢體功效測試市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲檢體功效測試市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區檢體功效檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲檢體功效測試市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲檢體功效測試市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球檢體功效檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Puritan Medical Products, LLC
• Becton and Dickinson Company
• Lucence Health Inc.
• Hardy Diagnostics Inc
• Medline Industries, LP
• Titan Biotech Ltd.
• Miraclean Technology Co., Ltd
• Starplex Scientific Inc.
• Diasorin SpA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Specimen Validity Testing Market is projected to expand from USD 3.26 Billion in 2025 to USD 4.95 Billion by 2031, reflecting a CAGR of 7.21%. This specialized screening process is utilized to verify the integrity of biological samples by detecting attempts to substitute, dilute, or adulterate specimens submitted for drug analysis. The market is primarily driven by strict regulatory mandates concerning workplace safety and the need for organizations to minimize liability in safety-sensitive industries. This demand is further amplified by the rising prevalence of substance misuse, which necessitates robust verification protocols to ensure test accuracy; for instance, the Substance Abuse and Mental Health Services Administration reported in 2024 that the proportion of individuals reporting illicit drug use in the past year rose to 25.5 percent, highlighting the urgent need for effective screening measures.

Despite these positive growth factors, the market faces significant challenges due to the evolving sophistication of sample tampering methods, such as the use of high-quality synthetic urine and advanced masking agents. These evasion tactics compel laboratories to continuously invest in complex analytical technologies, which increases operational costs and creates financial barriers for smaller testing facilities attempting to maintain comprehensive validity standards.

Market Driver

The rising global prevalence of illicit substance abuse acts as a primary catalyst for the specimen validity testing market, creating a critical need for rigorous screening protocols to confirm the authenticity of biological samples. As drug consumption rates increase internationally, laboratories must handle higher volumes of test subjects, which statistically raises the probability of encountering adulterated or substituted specimens designed to mask recent use. This surge in consumption forces testing facilities to integrate validity checks as a standard part of the analytical workflow to prevent false negatives and maintain accuracy. According to the United Nations Office on Drugs and Crime's 'World Drug Report 2024', the number of people using drugs globally reached 292 million in 2022, a 20 percent increase over the previous decade, underscoring the necessity for robust verification measures.

Market growth is further propelled by the expansion of workplace drug testing and corporate safety programs, particularly within safety-sensitive sectors like transportation and manufacturing. Employers are increasingly mandating comprehensive screening that includes validity parameters to mitigate legal liability and uphold operational safety standards, leading commercial laboratories to adopt automated validity testing to manage the influx of workforce samples. According to Quest Diagnostics' 'Annual Drug Testing Index' from May 2024, the general United States workforce drug positivity rate remained at 5.7 percent in 2023, highlighting the ongoing challenge employers face. Additionally, the European Monitoring Centre for Drugs and Drug Addiction estimated in 2024 that approximately 22.8 million adults in the EU used cannabis in the last year, reinforcing the need for consistent international validity standards.

Market Challenge

The evolving sophistication of sample tampering methods represents a substantial restraint on the Global Specimen Validity Testing Market. As individuals increasingly utilize advanced synthetic urine and masking agents to bypass standard screens, laboratories are compelled to invest in costly, high-precision analytical technologies. This necessity drastically raises operational expenses and capital requirements, creating significant financial barriers for smaller testing facilities that lack the resources to support such comprehensive validity standards.

Consequently, the market experiences reduced scalability as higher costs are passed to end-users and service availability becomes concentrated among larger providers. According to the National Drug-Free Workplace Alliance, the incidence of substituted urine specimens surged by over 600 percent in 2024, highlighting the rapid escalation of these evasion tactics. This sharp rise in tampering forces the industry to continuously divert resources toward expensive verification upgrades, which directly impedes the financial viability and expansion of the market.

Market Trends

The adoption of oral fluid specimen validity testing is gaining traction as a tamper-resistant alternative to traditional urine screening. Unlike urine collection, which requires privacy, oral fluid samples are collected under direct observation, significantly mitigating the risk of substitution or synthetic adulteration. This method naturally enhances specimen validity without requiring extensive secondary chemical analysis, driving its integration into regulatory frameworks. According to First Advantage's '2024 Annual Trends Report', the utilization of oral fluid-based drug screens grew by 74 percent over the last two years, now comprising 30 percent of all screening, indicating a strategic pivot toward testing matrices that inherently secure sample integrity.

Simultaneously, the market is shifting towards point-of-care (POC) testing solutions to facilitate immediate decision-making in safety-sensitive sectors. Organizations are increasingly deploying portable diagnostic tools that verify sample validity on-site, effectively bypassing the delays and custody complexities associated with central laboratory processing. These devices frequently incorporate automated validity checks to ensure specimen sufficiency and authenticity in real-time. According to OraSure Technologies' 'Third Quarter 2024 Financial Results', diagnostics segment revenues increased 13 percent year-over-year, driven by robust sales of rapid testing products, highlighting the industry's expanding reliance on decentralized screening methods that deliver instant, verified results.

Key Market Players

• Thermo Fisher Scientific Inc.
• Puritan Medical Products, LLC
• Becton and Dickinson Company
• Lucence Health Inc.
• Hardy Diagnostics Inc
• Medline Industries, LP
• Titan Biotech Ltd.
• Miraclean Technology Co., Ltd
• Starplex Scientific Inc.
• Diasorin S.p.A.

Report Scope

In this report, the Global Specimen Validity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specimen Validity Testing Market, By Product and Service

• Reagents
• Calibrators and Controls
• Assay Kits
• Disposables
• Services

Specimen Validity Testing Market, By Type

• Laboratory Testing
• Rapid/PoC Testing

Specimen Validity Testing Market, By End User

• Workplaces
• Drug Screening Laboratories
• Pain Management Centers
• Drug Rehabilitation Centers
• Others

Specimen Validity Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specimen Validity Testing Market.

Available Customizations:

Global Specimen Validity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specimen Validity Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product and Service (Reagents, Calibrators and Controls, Assay Kits, Disposables, Services)
  • 5.2.2. By Type (Laboratory Testing, Rapid/PoC Testing)
  • 5.2.3. By End User (Workplaces, Drug Screening Laboratories, Pain Management Centers, Drug Rehabilitation Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Specimen Validity Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product and Service
  • 6.2.2. By Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Specimen Validity Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product and Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Specimen Validity Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product and Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Specimen Validity Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product and Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End User

7. Europe Specimen Validity Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product and Service
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Specimen Validity Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product and Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Specimen Validity Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product and Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Specimen Validity Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product and Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Specimen Validity Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product and Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Specimen Validity Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product and Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Specimen Validity Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product and Service
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Specimen Validity Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product and Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Specimen Validity Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product and Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Specimen Validity Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product and Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Specimen Validity Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product and Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Specimen Validity Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product and Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Specimen Validity Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product and Service
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Specimen Validity Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product and Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Specimen Validity Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product and Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Specimen Validity Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product and Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User

10. South America Specimen Validity Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product and Service
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Specimen Validity Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product and Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Specimen Validity Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product and Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Specimen Validity Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product and Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Specimen Validity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Puritan Medical Products, LLC
• 15.3. Becton and Dickinson Company
• 15.4. Lucence Health Inc.
• 15.5. Hardy Diagnostics Inc
• 15.6. Medline Industries, LP
• 15.7. Titan Biotech Ltd.
• 15.8. Miraclean Technology Co., Ltd
• 15.9. Starplex Scientific Inc.
• 15.10. Diasorin S.p.A.

16. Strategic Recommendations

17. About Us & Disclaimer